A case report: euglycemic diabetic ketoacidosis presenting as severe abdominal pain and upper gastrointestinal bleed in a patient started on sglt2 inhibitor.
EuDKA caused by SGLT2 inhibitors is thought to be rare but real entity. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a relatively new class of oral antidiabetics for type 2 DM with renal and cardio protective benefits and acceptable safety profile. Although they are considered to be safe but US FDA issued a warning on use of SGLT-2 inhibitors about the risk of ketoacidosis. It is advised to health care professionals to consider the risk of EuDKA in patients who developed nausea, vomiting, abdominal pain, tiredness and difficulty in breathing while using it these drugs.